News
Investigators examined GLP-1 receptor agonist real-world effectiveness and safety in kidney transplant recipients with diabetes.
1d
MedPage Today on MSNLess Real-World GLP-1 Weight Loss; TROA Support; Rebuttal to Vitamin D GuidelinesResearchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...
Sometimes, the right advances in medicine catch the public’s imagination—opening a world of possibilities that inspires ...
1d
MedPage Today on MSNShould AMA 'Support' a Registry to Track Side Effects of GLP-1 Drugs?CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...
2d
HealthDay on MSNGLP-1 Receptor Agonist Exposure Linked to Neovascular AMD in Patients With DiabetesHealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...
China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its ...
5d
MedPage Today on MSNGLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA WarnsA potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...
GLP-1 drugs like Ozempic are associated with a higher risk of developing wet age-related macular degeneration in people with ...
Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...
The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...
Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results